Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial

Dai, Zhong-Liang1,2,3; Song, Yi-Feng1,2,3; Tian, Ya1,2,3; Li, Yin1,2,3; Lin, Miao1,2,3; Lin, Juan1,2,3; Wang, Qi1,2,3; Wang, Ping1,2,3; Gao, Wen-Li1,2,3

2021-10-01

10.1186/s12872-021-02287-w

BMC Cardiovascular Disorders   影响因子和分区

1471-2261

["Background: Trimetazidine (TMZ) pretreatment protects cardiomyocytes during cardiac surgery. TMZ may protect elderly patients with ischaemic heart disease (IHD) undergoing non-cardiac surgery.","Methods: This was a randomized, double-blind, placebo-controlled trial (registration #ChiCTR1900025018) of patients with IHD scheduled to undergo non-cardiac surgery at Shenzhen People's Hospital (Shenzhen, Guangdong Province, China) between June 2014 and September 2015, randomized to 60 mg TMZ or placebo 12 h before surgery. The primary endpoint was the occurrence of in-hospital cardiovascular events. The secondary endpoints were myocardial ischaemia on five-lead electrocardiogram (cECG), cardiac troponin I (cTnl) elevation, cardiac death, acute coronary events, heart failure, and arrhythmia requiring treatments.","Results: Compared with the placebo group, the TMZ group showed a lower occurrence of in-hospital cardiovascular events (primary endpoint, 20.0% vs. 37.5%, P=0.02), myocardial ischaemia (15.0% vs. 32.5%, P< 0.01), cTnl elevation (2.5% vs. 10%, P< 0.01), acute coronary events (10.0% vs. 20.0%, P< 0.05), heart failure (0% vs. 2.5%, P< 0.05), and arrhythmia requiring treatment (17.5% vs. 35.0%, P< 0.05). There was no acute myocardial infarction during the 30-day postoperative period.","Conclusions: In elderly patients with IHD undergoing non-cardiac surgery, TMZ pretreatment was associated with myocardial protective effects."]

Trimetazidine Elderly Surgery Myocardial ischaemia Complications

SCI

英语

通讯

Shenzhen Municipal Science and Technology Foundation[JCYJ20170307100314152] ; Shenzhen Health Research Fund["SZLY2018011","SZXJ2017029"] ; Guangdong Medical Research Fund["A2018008","A2019382"] ; Scientific Research Fund of Shenzhen People's Hospital[SYLY201706]

Cardiovascular System & Cardiology

Cardiac & Cardiovascular Systems

WOS:000702654400001

BMC

Web of Science

1.Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Anesthesiol, Shenzhen 518020, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen 518020, Guangdong, Peoples R China
3.Shenzhen Engn Res Ctr Anesthesiol, 1017 Dongmen North Rd, Shenzhen 518020, Guangdong, Peoples R China

Dai, Zhong-Liang,Song, Yi-Feng,Tian, Ya,et al. Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial[J]. BMC Cardiovascular Disorders,2021,21(1).

Dai, Zhong-Liang.,Song, Yi-Feng.,Tian, Ya.,Li, Yin.,Lin, Miao.,...&Gao, Wen-Li.(2021).Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial.BMC Cardiovascular Disorders,21(1).

Dai, Zhong-Liang,et al."Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial".BMC Cardiovascular Disorders 21.1(2021).